We confirmed a similar expression trend at the protein level (Figure 14B), suggesting that IGF2BP3 may be a potential molecular biomarker for the diagnosis and prognosis of glioma, especially GBM, which is expected to be a new therapeutic target for glioma. The gene discussed is IGF2BP3; the disease is central nervous system cancer.